Dieckhaus Kevin D, Kim Min-Jung, Shen Jian-Bing, Liang Tina S, Kleinberg Michael J, Siedlarz Kristen M, Banach David B, Metersky Mark L, Fuller Rob P, Mortensen Eric M, Liang Bruce T
UConn Health, Farmington, CT 06030, USA.
Vaccines (Basel). 2023 Feb 4;11(2):358. doi: 10.3390/vaccines11020358.
Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in reducing HCW susceptibility to SARS-CoV-2, however, neutralizing antibody responses subside with time and may be influenced by many variables. We sought to understand the dynamics between vaccine products, prior clinical illness from SARS-CoV-2, and incidence of vaccine-associated adverse reactions on antibody decay over time in HCWs at a university medical center. A cohort of 296 HCWs received standard two-dose vaccination with either bnt162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) and were evaluated after two, six, and nine months. Subjects were grouped by antibody decay curve into steep antibody decliners gentle decliners. Vaccination with mRNA-1273 led to more sustained antibody responses compared to bnt162b2. Subjects experiencing vaccine-associated symptoms were more likely to experience a more prolonged neutralizing antibody response. Subjects with clinical SARS-CoV-2 infection prior to vaccination were more likely to experience vaccination-associated symptoms after first vaccination and were more likely to have a more blunted antibody decay. Understanding factors associated with vaccine efficacy may assist clinicians in determining appropriate vaccine strategies in HCWs.
自严重急性呼吸综合征冠状病毒2（SARS-CoV-2）出现以来，维持医护人员（HCW）的健康与安全一直是应对全球大流行的根本。接种针对SARS-CoV-2刺突蛋白的mRNA疫苗已成为降低医护人员对SARS-CoV-2易感性的关键策略，然而，中和抗体反应会随时间减弱，且可能受多种变量影响。我们试图了解在一所大学医学中心，疫苗产品、既往SARS-CoV-2临床疾病以及疫苗相关不良反应的发生率与医护人员抗体随时间衰减之间的动态关系。一组296名医护人员接受了标准的两剂辉瑞/BioNTech的BNT162b2或莫德纳的mRNA-1273疫苗接种，并在2个月、6个月和9个月后进行评估。根据抗体衰减曲线将受试者分为抗体快速衰减者和缓慢衰减者。与BNT162b2相比，接种mRNA-1273可产生更持久的抗体反应。出现疫苗相关症状的受试者更有可能经历更长时间的中和抗体反应。接种疫苗前有SARS-CoV-2临床感染的受试者在首次接种后更有可能出现疫苗相关症状，且抗体衰减更平缓。了解与疫苗效力相关的因素可能有助于临床医生确定医护人员的合适疫苗策略。
